ThermoGenesis Holdings, Inc. (NASDAQ:THMO) dropped 0.4% during mid-day trading on Monday . The stock traded as low as $2.30 and last traded at $2.38. Approximately 59,025 shares traded hands during trading, a decline of 91% from the average daily volume of 690,035 shares. The stock had previously closed at $2.39.
Separately, Zacks Investment Research raised shares of ThermoGenesis from a “sell” rating to a “hold” rating in a research note on Thursday, August 12th.
The firm has a market capitalization of $27.52 million, a P/E ratio of -1.92 and a beta of 3.23. The company’s 50 day moving average is $2.35 and its 200-day moving average is $2.55. The company has a quick ratio of 0.86, a current ratio of 1.35 and a debt-to-equity ratio of 0.08.
Several institutional investors have recently added to or reduced their stakes in THMO. Vanguard Group Inc. lifted its stake in shares of ThermoGenesis by 276.4% in the second quarter. Vanguard Group Inc. now owns 259,610 shares of the company’s stock valued at $688,000 after buying an additional 190,645 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of ThermoGenesis in the first quarter valued at $244,000. Goldman Sachs Group Inc. lifted its stake in shares of ThermoGenesis by 106.9% in the first quarter. Goldman Sachs Group Inc. now owns 49,769 shares of the company’s stock valued at $134,000 after buying an additional 25,711 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of ThermoGenesis in the second quarter valued at $59,000. Finally, State Street Corp purchased a new stake in shares of ThermoGenesis in the second quarter valued at about $45,000. 3.80% of the stock is currently owned by hedge funds and other institutional investors.
ThermoGenesis Company Profile (NASDAQ:THMO)
ThermoGenesis Holdings, Inc engages in the research, development, commercialization, and marketing of automated cell processing technologies for the cell and gene therapy field. It operates through the Device and Clinical Development segment. The Device segment includes the development and commercialization of automated technologies for cell-based therapeutics and bioprocessing.
Featured Article: What are the disadvantages of after-hours trading?
Receive News & Ratings for ThermoGenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesis and related companies with MarketBeat.com's FREE daily email newsletter.